 Home > Active Ingredient News > Antitumor Therapy > Liver Cancer: Real-World Efficacy of Lenvatinib in Hepatocellular Carcinoma: A Retrospective Multicenter Study (ELEVATOR)

Liver Cancer: Real-World Efficacy of Lenvatinib in Hepatocellular Carcinoma: A Retrospective Multicenter Study (ELEVATOR)

 Last Update: 2022-01-23
 Source: Internet
 Author: User

Tags

morgellons disease treatment

evo 9 years

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Lenvatinib has been approved as a first-line treatment for advanced hepatocellular carcinoma (HCC)
.
The real-world efficacy of lenvatinib in Caucasian patients is unclear

Lenvatinib has been approved as a first-line treatment for advanced hepatocellular carcinoma (HCC)

Retrospective data analysis of 205 patients who received lenvatinib first-line systemic therapy at 14 centers

Of the 205 patients included, the median age at initiation of treatment was 69 years, and 81.

Median overall survival (OS) was 12.

According to the REFLECT study criteria, 205 patients could be divided into 110 patients who met the criteria (REFLECT-in) and 95 patients who did not meet the criteria (REFLECT-out)

Patients with good liver function (ALBI grade 1) had significantly longer mOS than patients with ALBI grade 2 or ALBI grade 3 (ALBI grade 1: 19.

9 months, ALBI grade 2: 11.

Patients with good liver function (ALBI grade 1) had significantly longer mOS than patients with ALBI grade 2 or ALBI grade 3 (ALBI grade 1: 19.

Responders had significantly longer median OS than non-responders (23.

9 months vs 10.

Responders had significantly longer median OS than non-responders (23.

Median OS was 15.

9 months vs 8.
6 months in patients with or without subsequent antineoplastic therapy (HR 0.
45, 95% CI 0.
30-0.
66; p≦0.
001)
.

Median OS was 15.
9 months vs 8.
6 months in patients with or without subsequent antineoplastic therapy (HR 0.
45, 95% CI 0.
30-0.
66; p≦0.
001)
.
Median OS was 15.
9 months vs 8.
6 months in patients with or without subsequent antineoplastic therapy (HR 0.
45, 95% CI 0.
30-0.
66; p≦0.
001)
.

Factors significantly associated with OS were: REFLECT-in and -out (HR 0.
55, 95% CI 0.
38-0.
81, p=0.
002), ALBI class (ALBI 1 vs ALBI 2 HR 2.
07, 95% CI 1.
34-3.
19, p= 0.
001; ALBI 1 vs ALBI 3 HR 2.
80, 95% CI 1.
43-5.
52, p=0.
003) and Child Pugh score (HR 0.
42, 95% CI 0.
27-0.
63, p=<0.
001), ECOG ≥2 (ECOG 0 vs ECOG 2 HR 2.
17, 95% CI 1.
22-3.
85, p=0.
005, ECOG 0 vs ECOG 1 HR 1.
13, 95% CI 0.
75-1.
7, p=0.
563), large vessel invasion (no vs yes, HR 1.
78, 95% CI 1.
22 -2.
60, p=0.
003,) and AFP levels (AFP <200ng/mL vs AFP ≥200ng/mL, HR 1.
74, 95% CI 1.
19-2.
54, p=0.
004)
.

Multivariate analysis, macrovascular invasion (HR 1.
55, 95% CI 1.
02-2.
37, p=0.
041), ECOG=2 (HR 2.
25, 95% CI 1.
19-4.
23, p=0.
012), AFP ≥200ng/ml (HR 1.
56 , 95% CI 1.
03-2.
34, p=0.
034), and ALBI classification (HR 1.
69; 95% CI 1.
07-2.
66, p=0.
023) was an independent negative factor
.
Multivariate analysis, macrovascular invasion (HR 1.
55, 95% CI 1.
02-2.
37, p=0.
041), ECOG=2 (HR 2.
25, 95% CI 1.
19-4.
23, p=0.
012), AFP ≥200ng/ml (HR 1.
56 , 95% CI 1.
03-2.
34, p=0.
034), and ALBI classification (HR 1.
69; 95% CI 1.
07-2.
66, p=0.
023) was an independent negative factor
.
Multivariate analysis, macrovascular invasion (HR 1.
55, 95% CI 1.
02-2.
37, p=0.
041), ECOG=2 (HR 2.
25, 95% CI 1.
19-4.
23, p=0.
012), AFP ≥200ng/ml (HR 1.
56 , 95% CI 1.
03-2.
34, p=0.
034), and ALBI classification (HR 1.
69; 95% CI 1.
07-2.
66, p=0.
023) was an independent negative factor
.

In conclusion, this real-world data study once again demonstrated the efficacy of Lenvatinib in the treatment of hepatocellular carcinoma
.

In conclusion, this real-world data study once again demonstrated the efficacy of Lenvatinib in the treatment of hepatocellular carcinoma
.
This real-world data study once again demonstrated the efficacy of Lenvatinib in the treatment of hepatocellular carcinoma
.
This real-world data study once again demonstrated the efficacy of Lenvatinib in the treatment of hepatocellular carcinoma
.

Original source:

Welland S, Leyh C, Finkelmeier F, et al.
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A retrospective multicenter study.
Liver Cancer, Published online: January 14, 2022, DOI: 10.
1159/000521746.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.